Effectiveness of Vedolizumab Induction Therapy in IBD Patients

被引：0
|
作者：
Kaymak, Tanay [1 ]
Niess, Jan H. [1 ]
Hruz, Petr [1 ]
机构：
[1] Univ Hosp Basel, Dept Gastroenterol & Hepatol, Basel, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2017年 / 147卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PG14
引用
收藏
页码：16S / 16S
页数：1
相关论文
共 50 条
  • [31] Outcome of pregnancies in female IBD patients treated with vedolizumab
    Moens, A.
    van Hoeve, K.
    Humblet, E.
    Rahier, J-F.
    Bossuyt, P.
    Dewit, S.
    Franchimont, D.
    Macken, E.
    Nijs, J.
    Posen, A.
    Van Hootegem, A.
    Van Moerkercke, W.
    Vermeire, S.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S22 - S23
  • [32] Vedolizumab Safety Profile in Treatment of Elderly IBD Patients
    Marnoy, Zachary
    Grossberg, Laurie
    Hartwell, Nathan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S1589 - S1589
  • [33] New onset spondyloarthropathy in vedolizumab treated IBD patients
    Tetley, A. M.
    Lobaton, T.
    Truyens, M.
    Katsanos, K. H.
    de Boer, K. H. N.
    Pattinson, A.
    Molnar, T.
    Filip, R.
    Michalopoulos, G.
    Sebastian, S.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S568 - S568
  • [34] Faecal calprotectin is correlated to endoscopic disease activity at Week 16 in IBD patients on vedolizumab therapy
    Pauwels, R. W. M.
    De Vries, A. C.
    Van der Woude, C. J.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S324 - S324
  • [35] COMBINATION THERAPY OF VEDOLIZUMAB AND A TNF ANTAGONIST IN IBD PATIENTS WITH SEVERE CHRONIC ACTIVE, THERAPY REFRACTORY DISEASE COURSE
    Kuehbacher, Tanja
    AbuHashem, Raed
    Langel, Natalie
    Schreiber, Stefan
    Drvarov, Oliver
    GASTROENTEROLOGY, 2017, 152 (05) : S398 - S398
  • [36] Combination therapy of vedolizumab and a TNF antagonist in IBD patients with severe chronic active, therapy refractory disease course
    Kuehbacher, T.
    Abu Hashem, R.
    Langel, N.
    Schreiber, S.
    Drvarov, O.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S357 - S357
  • [37] Changes in Patient-Reported Outcomes With Vedolizumab Therapy in Patients With Inflammatory Bowel Diseases (IBD)
    Long, Millie D.
    Martin, Christopher
    Chen, Wenli
    Jaeger, Elizabeth
    Barocas, Morris
    Luo, Michelle
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S342 - S342
  • [38] THE USE OF VEDOLIZUMAB MAY INCREASE THE RISK OF CLOSTRIDIUM DIFFICILE INFECTION IN IBD PATIENTS ON BIOLOGIC THERAPY
    Martinez-Lozano, Helena
    Garcia, Aurea Garcia
    Gonzalez, Paula Saralegui
    Ramirez, Elena Reigadas
    Castillo, Diego Hernandez
    Hernandez, Luis Alcala
    Munoz, Patricia
    Miranda-Bautista, Jose
    Marin-Jimenez, Ignacio
    Menchen, Luis
    GASTROENTEROLOGY, 2023, 164 (06) : S431 - S431
  • [39] COMBINATION THERAPY OF VEDOLIZUMAB AND TOFACITINIB IN IBD PATIENTS WITH CHRONIC ACTIVE REFRACTORY DISEASE COURSE AND SPONDYLARTHRITIS
    Kuehbacher, Tanja
    Leick, Angele
    Vongogh, Gwendolyn
    Porthun, Markus
    Schreiber, Stefan
    Cederqvist, Marco
    GASTROENTEROLOGY, 2019, 156 (06) : S881 - S881
  • [40] Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis
    Hu, Qiong
    Tang, Xing-zhou
    Liu, Fang
    Liu, De-wu
    Cao, Bo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
12345